- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04184544
Scaling up Evidence Based MNCH Interventions : A Quasi Experimental Study Umeed e Nau (UeN) Project (UeN)
Supporting Women and Girls in Pakistan: Scaling up Empowerment and Care Strategies to Address Health and Survival
Study Overview
Status
Intervention / Treatment
Detailed Description
Pakistan's continued high maternal, neonatal, and child mortality is affecting the overall development and national growth. The estimated national maternal mortality ratio ranges from 250 - 750 per 100,000 live births per year, while neonatal mortality rate ranges from 43 - 66 per 1,000 live births per year across the provinces of Pakistan. The under-five mortality rate is 89 per 1,000 live births per year, and diarrhea and pneumonia are two of the most common causes of post-neonatal mortality. Together, they account for more than 30% of all under five deaths in Pakistan.
Majority of maternal, newborn and child deaths are preventable and treatable given programs are designed and delivered through an efficient public health system that takes into account the geographic and social structures. There are several factors resulting in slow progress and improvement of MNCH indicators. These include poor coverage, delayed scale up of effective interventions within the existing health system platforms, lack of women's and girls' empowerment, voice, and participation, and lack of community awareness and support regarding health conditions and poverty. Many of the risk factors that impact maternal and newborn health, such as nutritional deficiencies, exist from adolescence, and becoming pregnant during this sensitive life stage has been found to slow and stunt one's growth In order to evaluate the impact of the UeN initiative quasi experimental study design will be used. The intervention groups are broadly divided into two groups. Both groups will serve as control against each other due to nature of targeting of age group by each intervention group type. Group one included maternal and newborn health districts. These districts are further divided into three sub groups. Sub group 1 will receive only interventions focusing on maternal health (1 district (Sangher)); sub group 2 will receive interventions focusing only on newborn health (1 district (Nasirabad)); sub group 3 will receive combined maternal and newborn interventions (two districts (Lasbila and Badin). Group two will receive child health interventions focusing on the implementation of the global action plan for pneumonia and diarrhea (GAPPD [4districts, Qamabar Shahdadkot Muzaffargarh, Rahim Yar Khan Jafferabad). This design will help us to evaluate independent and combined effect of maternal, newborn, and child health interventions to address maternal, newborn and child health outcomes. We hypothesize that the roll out of proven and effective interventions within existing health delivery platforms for maternal, newborn, child and adolescent health will lead to significant reduction in perinatal mortality rate (20% compared to baseline) and at least 30% reduction in diarrhea and pneumonia case fatality rate in the target project districts.
UeN design justification: The conceptual framework for UeN postulates that increased engagement with communities, empowering women and girls, including addressing access barriers; 2) strengthening capacity of the public and private health sectors mainly through revision of curricula based on new evidence, developing management protocols for different cadre of health workers and providers on MNCH and training; private Sector engagement; 3) provision of sustained supplies and 4) District Health Information System (DHIS) data use for decision making will lead to greater responsiveness of public and private service providers to women's and girls' needs - particularly those of undeserved women, girls and children. The UeN initiative aims to create opportunities in governance processes through revival and participation in District Health Management team (DHMTs), service delivery and citizens' voice and empowerment to transform public and private health sector interactions to drive improvements in MNCH and survival
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 47800
- Aga khan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All women of reproductive age in the project areas
- All children under the age of five years
Exclusion Criteria:
- The subjects not residing in the project catchment population
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Maternal and Newborn health districts
Group one included maternal and newborn health districts.
These districts are further divided into three sub groups.
Sub group 1 will receive only interventions focusing on maternal health (1 district (Sangher)); sub group 2 will receive interventions focusing only on newborn health (1 district (Nasirabad)); sub group 3 will receive combined maternal and newborn interventions (two districts (, Lasbila and Badin).
|
Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
|
|
Experimental: Child Health
Group two will receive child health interventions focusing on the implementation of the global action plan for pneumonia and diarrhea (GAPPD [4districts, Qamabar Shahdadkot Muzaffargarh, Rahim Yar Khan Jafferabad).
|
Community Mobilization and engagement; Use of DHIS data for decision making; Capacity building of health care workers and providers and other Community level and facility level interventions to improve MNCH outcomes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perinatal deaths
Time Frame: three years
|
20% reduction in perinatal mortality
|
three years
|
|
case fatality rate
Time Frame: Three years
|
30% reduction in Pneumonia and diarrhea case fatality in participating health facilities
|
Three years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zulfiqar A Bhutta, PhD, AKU
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0979-3131
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Newborn Morbidity
-
Assumpta Solome NantumeDLR German Aerospace Center; Academic Model Providing Access to Healthcare...RecruitingNewborn Morbidity | Newborn ComplicationKenya
-
University of Alabama at BirminghamCompletedNewborn MorbidityUnited States
-
Universidad Autonoma de Nuevo LeonCompletedHospital Readmission | Newborn Morbidity | Newborn | Newborn Complication
-
Julie LefevereCompletedNewborn MorbidityBelgium
-
Konya City HospitalCompleted
-
Hacettepe UniversityCompletedSurgery--Complications | Newborn Morbidity | Neonatal SurgeryTurkey
-
Universidad de la SabanaCompletedTelemedicine | Newborn Morbidity | Simulation Training | Assessment, SelfColombia
-
Aga Khan UniversityBill and Melinda Gates FoundationCompleted
-
Universidade Metodista de PiracicabaRecruiting
-
Benha UniversityCompletedNewborn Morbidity | Anesthesia; Adverse EffectEgypt
Clinical Trials on Improving of quality of care at health facility and outreach level
-
WestatNational Institute on Drug Abuse (NIDA); Eunice Kennedy Shriver National Institute... and other collaboratorsNot yet recruitingHIV | HIV Prevention | STIs | STIs PreventionUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedStroke, Ischemic | Large Vessel OcclusionFrance
-
Memorial Sloan Kettering Cancer CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | APC Gene Mutation | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | PTEN Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6 Gene Mutation | PMS2 Gene Mutation | POLD1 Gene... and other conditionsUnited States
-
CHU de Quebec-Universite LavalRecruitingImmunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager (CHUQUL_HO001)Relapsed Multiple Myeloma | Multiple Myeloma RefractoryCanada
-
University Hospital, RouenNot yet recruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruitingTaste Disorders | Olfactory Disorder | Smell Disorder | Smell DysfunctionBelgium
-
Nordic Society of Gynaecological Oncology - Clinical...RecruitingOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CancerDenmark
-
Istinye UniversityNot yet recruitingPostoperative HypoxemiaTurkey (Türkiye)
-
Fox Chase Cancer CenterPfizer; University of Alabama, Tuscaloosa; Institut de Recherche en Sciences... and other collaboratorsRecruiting
-
Alnylam PharmaceuticalsActive, not recruitingHereditary Amyloidosis, Transthyretin-Related | Asymptomatic Carrier StateFrance